Healthy volunteers help uncover drug interaction for prostate cancer therapy
NCT ID NCT07014488
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study looked at how the antibiotic rifampicin changes the way the body processes HRS-5041, a potential prostate cancer drug. Sixteen healthy men took HRS-5041 tablets with and without rifampicin to measure drug levels and safety. The goal was to gather information for future dosing recommendations, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, 250014, China
Conditions
Explore the condition pages connected to this study.